Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia

GUO Xing; ZHAO Dan; ZUO Jinman

doi:10.6039/j.issn.1001-0408.2023.23.17

您当前的位置：

首页 >

文章列表页 >

Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia

更新时间：2025-09-23

- Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia
- ZHONGGUO YAOFANG Vol. 34, Issue 23, Pages: 2910-2914(2023)
- 作者机构：
  
  1.蚌埠医学院第二附属医院药学部，安徽蚌埠　233020
  2.蚌埠市第三人民医院药学部，安徽蚌埠　233099
  3.蚌埠医学院第二附属医院血液内科，安徽蚌埠　233020
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.23.17
  CLC： R973;R558+.2
- Received：06 May 2023，
  
  Revised：2023-11-15，
  
  Accepted：15 November 2023，
  
  Published：15 December 2023
- 稿件说明：
移动端阅览
郭星,赵丹,左金曼.海曲泊帕联合重组人血小板生成素治疗原发免疫性血小板减少症的临床观察[J].中国药房,2023,34(23):2910-2914.

GUO Xing,ZHAO Dan,ZUO Jinman.Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia[J].ZHONGGUO YAOFANG,2023,34(23):2910-2914.
郭星,赵丹,左金曼.海曲泊帕联合重组人血小板生成素治疗原发免疫性血小板减少症的临床观察[J].中国药房,2023,34(23):2910-2914. DOI： 10.6039/j.issn.1001-0408.2023.23.17.

GUO Xing,ZHAO Dan,ZUO Jinman.Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia[J].ZHONGGUO YAOFANG,2023,34(23):2910-2914. DOI： 10.6039/j.issn.1001-0408.2023.23.17.

摘要

目的

探讨海曲泊帕联合重组人血小板生成素（rhTPO）治疗原发免疫性血小板减少症（ITP）在真实世界中的临床疗效和安全性。

方法

回顾性选取2021年1月至2022年12月蚌埠医学院第二附属医院诊断为ITP的患者，将其中使用海曲泊帕联合rhTPO的98例患者设为观察组，使用rhTPO的157例患者设为对照组。观察并比较2组患者治疗前后的血小板计数、临床疗效、出血情况、血小板输注率和不良反应发生情况。

结果

从治疗第8天[观察组为（61.04±13.46）×10

－1

，对照组为（52.11±12.06）×10

－1

]

开始，2组患者的血小板计数差异有统计学意义（

＜0.05），且2组患者血小板计数的峰值和稳定值差异均有统计学意义（

＜0.05）。观察组与对照组患者的总有效率分别为79.59%和66.88%，累积达终点率分别为81.32%与68.68%，中位有效时间分别为8 d和10 d，差异均有统计学意义（

＜0.05）。治疗期间观察组与对照组患者的出血率分别为3.06%和8.28%（

＜0.05），出血等级均为1级或2级；血小板输注率分别为31.63%和40.76%，差异有统计学意义（

＜0.05）。2组患者不良反应发生率分别为11.22%和9.55%，差异无统计学意义（

＞0.05），且均无中重度不良反应记录。

结论

海曲泊帕联合rhTPO能显著提高ITP患者的血小板水平和有效率，降低出血率和血小板输注率，并具有良好的安全性。

Abstract

OBJECTIVE

To investigate the clinical efficacy and safety of herombopag combined with recombinant human thrombopoietin （rhTPO） in the treatment of primary immune thrombocytopenia （ITP） in the real world.

METHODS

A retrospective study was conducted on the patients diagnosed with ITP in the Second Affiliated Hospital of Bengbu Medical College from January 2021 to December 2022. Among them， 98 patients who were treated with a combination of herombopag and rhTPO were included in the observation group， and 157 patients who were treated with rhTPO alone were included in the control group. The changes in platelet count， clinical efficacy， bleeding， platelet transfusion rate and adverse drug reactions before and after treatment were observed and compared between the two groups.

RESULTS

Since the 8th day of treatment， there was a statistically significant difference in platelet count between the two groups [（61.04±13.46）×10

－1

in observation group，（52.11±12.06）×10

－1

in control group

]

（

＜0.05）， and there also was a statistically significant difference in the peak and stable values of platelet count between the two groups （

＜0.05）. The total effective rates of the observation group and the control group were 79.59% and 66.88%， with cumulative response rates of 81.32% and 68.68%， and median response durations of 8 days and 10 days， respectively； these differences were statistically significant （

＜0.05）. During the treatment period， the bleeding rates of the observation group and control group were 3.06% and 8.28% （

＜0.05）， bleeding events were categorized as grade 1 or 2， and platelet transfusion rates were 31.63% and 40.76%； the differences in bleeding rates and platelet transfusion rates between the two groups was statistically significant （

＜0.05）. The incidences of adverse drug reactions in the two groups were 11.22% and 9.55%， respectively， with no statistically significant difference （

＞0.05）， and no moderate to severe adverse drug reaction was found.

CONCLUSIONS

The combination of herombopag and rhTPO can significantly increase platelet levels and response rate， and reduce bleeding rate and platelet transfusion rate in ITP patients， with good safety.

关键词

Keywords

references

AUDIA S ， MAHÉVAS M ， SAMSON M ， et al . Pathogene- sis of immune thrombocytopenia [J ] . Autoimmun Rev ， 2017 ， 16 （ 6 ）： 620 - 632 .

KHELLAF M ， VIALLARD J F ， HAMIDOU M ， et al . A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia [J ] . Haematologica ， 2013 ， 98 （ 6 ）： 881 - 887 .

KIM Y K ， LEE S S ， JEONG S H ， et al . Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia [J ] . Blood Res ， 2015 ， 50 （ 1 ）： 19 - 25 .

PARK R . Eltrombopag：a new treatment option for chronic refractory adult immune thrombocytopenia [J ] . Blood Res ， 2015 ， 50 （ 1 ）： 1 - 2 .

SYED Y Y . Hetrombopag：first approval [J ] . Drugs ， 2021 ， 81 （ 13 ）： 1581 - 1585 .

WANG Z L ， CHEN L ， ZHANG F K ， et al . First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura [J ] . J Thromb Haemost ， 2020 ， 18 （ 11 ）： 3053 - 3060 .

ZHENG L ， LIANG M Z ， ZENG X L ， et al . Safety，pharmacokinetics and pharmacodynamics of hetrombopag olamine，a novel TPO-R agonist，in healthy individuals [J ] . Basic Clin Pharmacol Toxicol ， 2017 ， 121 （ 5 ）： 414 - 422 .

XIE C Y ， ZHAO H J ， BAO X B ， et al . Pharmacological characterization of hetrombopag，a novel orally active human thrombopoietin receptor agonist [J ] . J Cell Mol Med ， 2018 ， 22 （ 11 ）： 5367 - 5377 .

中华医学会血液学分会血栓与止血学组 . 成人原发免疫性血小板减少症诊断与治疗中国指南：2020年版 [J ] . 中华血液学杂志， 2020 ， 41 （ 8 ）： 617 - 623 .

Thrombosis and Hemostasis Group，HematologyBranch，Chinese Medical Association . Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia：version 2020 [J ] . Chin J Hematol ， 2020 ， 41 （ 8 ）： 617 - 623 .

PUAVILAI T ， THADANIPON K ， RATTANASIRI S ， et al . Treatment efficacy for adult persistent immune thrombocytopenia：a systematic review and network meta-analysis [J ] . Br J Haematol ， 2020 ， 188 （ 3 ）： 450 - 459 .

FOGARTY P F ， TARANTINO M D ， BRAINSKY A ， et al . Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia [J ] . Curr Med Res Opin ， 2012 ， 28 （ 1 ）： 79 - 87 .

NEUMANN A ， ŽIŽKA Z ， KOUCKÝ M ， et al . Fetal and neonatal alloimmune thrombocytopenia [J ] . Ceska Gynekol ， 2018 ， 83 （ 6 ）： 448 - 451 .

LEE J Y ， LEE J H ， LEE H ， et al . Epidemiology and ma- nagement of primary immune thrombocytopenia：a nationwide population-based study in Korea [J ] . Thromb Res ， 2017 ， 155 ： 86 - 91 .

MOULIS G ， PALMARO A ， MONTASTRUC J L ， et al . Epidemiology of incident immune thrombocytopenia：a nationwide population-based study in France [J ] . Blood ， 2014 ， 124 （ 22 ）： 3308 - 3315 .

BASCIANO P A ， BUSSEL J B . Thrombopoietin-receptor agonists [J ] . Curr Opin Hematol ， 2012 ， 19 （ 5 ）： 392 - 398 .

GHANIMA W ， COOPER N ， RODEGHIERO F ， et al . Thrombopoietin receptor agonists：ten years later [J ] . Haematologica ， 2019 ， 104 （ 6 ）： 1112 - 1123 .

PENG G X ， HE G S ， CHANG H ， et al . A multicenter phase Ⅱ study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy [J ] . Ther Adv Hematol ， 2022 ， 13 ： 20406207221085197 .

MEI H ， LIU X F ， LI Y ， et al . A multicenter，randomized phase Ⅲ trial of hetrombopag：a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia [J ] . J Hematol Oncol ， 2021 ， 14 （ 1 ）： 37 .

WINER E S ， SAFRAN H ， KARASZEWSKA B ， et al . Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy：a randomized，placebo-controlled phase 2 study [J ] . Int J Hematol ， 2017 ， 106 （ 6 ）： 765 - 776 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤协会（CSCO）肿瘤治疗所致血小板减少症诊疗指南：2023 [M ] . 北京：人民卫生出版社， 2023 ： 20 ， 38 .

Guidelines Working Committee of the Chinese Clinical Oncology Society . Chinese Clinical Oncology Association （CSCO） guidelines for the diagnosis and treatment of thrombocytopenia caused by tumor therapy：2023 [M ] . Beijing ： People’s Health Publishing House ， 2023 ： 20 ， 38 .

Views

247

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Clinical observation of doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children under 8 years of age

Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer

Clinical observation of vonoprazan-based triple therapy in treatment-naive patients with Helicobacter pylori infection

Comparison of the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome patients after percutaneous coronary intervention

Related Author

WANG Wanwan

YE Jun

CHENG Hai

YAO Wei

LIU Guiling

LI Shanshan

ZHENG Jishan

CHEN Yanyan

Related Institution

Dept. of Hematology， the Third People’s Hospital of Bengbu

Dept. of Hematology， the Affiliated Hospital of Xuzhou Medical University

Dept. of Pharmacy， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Paediatrics， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Pharmacy， the Affiliated Hospital of Zunyi Medical University

⁰